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Standfirst: The enteric lipid metabolite, 12,13-diHOME, produced by the gut microbiome 
promotes an asthma-like immunophenotype in the lungs of a murine experimental model. 
Accordingly, the metabolite is elevated in neonates who developed asthma during childhood, 
potentially providing a biomarker for early risk prediction and a novel therapeutic target. 
 
 
 
The gut microbiome is increasingly recognised to play diverse roles in human health and 
disease, yet the mechanisms by which these intestinal microbial communities influence other 
regions of the human body have yet to be fully determined. Recent work by Levan et al. 
points to the bacterially produced lipid metabolite, 12,13-diHOME, as one possible link 
between the gut microbiome, lung immunity, and the development of asthma in childhood1.  
 
Reporting in Nature Microbiology1, Lynch and colleagues further their previous work on the 
pathogenic role of 12,13-diHOME in the gut-lung axis. They previously demonstrated that 
this metabolite is found at higher concentrations in the gut of neonates who go on to develop 
childhood atopy and asthma2. Through a series of innovative experiments that began in vivo 
(Figure 1), the authors found that peritoneal administration of 12,13-diHOME to mice, that 
were later sensitised and challenged with cockroach allergen, led to an overall increased 
inflammatory response. This included increased pulmonary leukocyte infiltration, with an 
associated increase in IL-1β, IL-1α and TNF expression, and decreased regulatory T cell 
(Treg) numbers in the lung. The 12,13-diHOME levels were higher in the plasma and lungs of 
treated mice, providing further evidence that gut derived metabolites can enter the circulation 
and promote allergy in other organs. Lynch and colleagues then determined in vitro that 
exposure to 12,13-diHOME led to reduced IL-10 secretion by dendritic cells. 12,13-diHOME 
was shown to activate the lipid receptor peroxisome proliferator-activated gamma (PPARγ) 
on dendritic cells, resulting in reduced expression of the surface proteins CD1a and CD80, 
responsible for lipid and antigen presentation. The authors postulate this to be one of 
potentially several mechanisms by which 12,13-diHOME promotes allergy.  
 
Next, the authors turned to two established neonatal cohorts and employed metagenomic 
sequencing of faecal samples. They sought to identify microbial species and their genes 
associated with asthma, paying particular attention to epoxide hydrolase (EH) enzymes, 
owing to their role in producing 12,13-diHOME. Bacterial EH genes were more abundant in 
the gut microbiome of neonates who later went onto develop childhood asthma, and three 
strain-specific bacterial EH genes in particular were responsible for the production of 12,13-
diHOME. Furthermore, while all neonates had detectable faecal 12,13-diHOME, levels were 
higher in neonates with greater abundance of the three bacterial EH genes. The functional 
consequences of these genes in vivo were tested by over-expression in E coli, followed by 
oral supplementation of these bacteria to mice exposed to the cockroach antigen as part of the 
allergic airway inflammation model. This resulted in higher 12,13-diHOME levels in the 
plasma with an associated reduction in the number of pulmonary Treg, mirroring the tissue 
phenotype of peritoneal administration of the metabolite observed in the initial in vivo 
experiments. 
 
The neonatal period has been described as the ‘window of opportunity’ for detection and 
intervention in atopy and asthma. The microbiome and immune system undertake constant 
crosstalk and unlike microbiome-host interactions in later life, during the neonatal period 
these conversations are happening for the first time. Breast feeding has been reported to be 
the most important factor influencing the development of the gut microbiome in early life3,4 
and meta-analyses have reported overall that breast feeding is associated with a reduced risk 
of developing asthma5,6. Whether breast milk is implicated in reducing the abundance of 
bacteria containing the three EH genes responsible for the generation of 12,13-diHOME has 
not been explored, but may represent one mechanism underlying the beneficial effects of 
breast feeding. One must also consider the potentially beneficial role of microbial metabolites 
produced by the gut microbiome, including short chain fatty acids (SCFAs). Unlike 12,13-
diHOME mediated effects, microbially-derived SCFAs in the gut promote Treg 
differentiation7 and enhance bone marrow production of dendritic cells that have an impaired 
ability to stimulate Th2 allergic inflammation in the lung8. Ultimately, early prediction and a 
better understanding of the underlying disease processes offers novel avenues for clinical 
management and early intervention of atopy and asthma. For instance, reducing the 
abundance of gut microorganisms carrying the three EH genes responsible for the generation 
of 12,13-diHOME and promoting SCFA producing microorganisms. 
 
12,13-diHOME was first associated with the development of childhood atopy and asthma 
following an untargeted metabolomic analysis of only 28 neonatal faecal samples2. In 
metabolomics, accurate identification requires standard compounds to be analysed alongside 
the samples of interest, and one might expect hundreds of features to be identified, meaning 
several thousand will remain unidentified. As the metabolite standard libraries expand, it 
seems plausible that other ‘12,13-diHOME-like’ metabolite products of the gut microbiome 
may be discovered. Equally, 12,13-diHOME is likely to act on more host cell targets than 
PPARγ, which is acknowledged by Lynch and colleagues. Improvements in microbial 
sequencing methods should also facilitate the exploration of gene transcription, providing 
more information on specific bacterial functions. Subsequent exploration of microorganism-
produced metabolites and their host cell targets will paint a more complete picture of the 
underlying pathobiology in childhood atopy and asthma. 
 
The dedicated work by Lynch and colleagues over the past five years has truly put 12,13-
diHOME on the (metabolic) map and demonstrates that the gut-lung axis may represent a 
tangible modality for risk stratification or therapeutic manipulation in childhood asthma. This 
work represents an exemplar of building from multi ‘omic discovery research to identify 
microbial associations with human disease, through experiments to address function and 
causality, to the ultimate goal of providing proof of concept to underpin translational or 
experimental medicine initiatives. 
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